Novartis cans its Japanese brass; Crescendo closes $32.3M A round;

@FierceBiotech: Party drug turned 'miracle' cure for depression spurs hype and stubborn hope. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Celgene pays VCs $47M to up its stake in Acceleron's pipeline. More | Follow @JohnCFierce

@DamianFierce: Looking back at notes from JPM in January, Lumena said it would wait on IPO until it had more data, to drive up valuation. That was pre-Q1 boom. | Follow @DamianFierce

@EmilyMFierce: Mutations during vaccine making weakened last year's flu jab. Article via FierceVaccines | Follow @EmilyMFierce

> Novartis ($NVS) has sent some of its top Japanese execs packing as allegations of clinical trial misconduct have plagued the drugmaker. News

> Crescendo Biologics has banked another $3.3 million in the final close of its Series A financing, bringing the total to $32.3 million. Release

> Otologic Pharmaceutics raised a $4.1 million Series A to advance its lead candidate, NHPN-1010 for noise-induced hearing loss. Item

Medical Device News

@FierceMedDev: Breaking: Cardinal Health is snatching up device maker AccessClosure for $320M. Story | Follow @FierceMedDev

@MarkHFierce: Last year, my sister died, and I learned first-hand about life sciences' limits. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: ICYMI: The year in nanotech drug delivery. Report | Follow @MichaelGFierce

@EmilyWFierce: The FDA approved a hand-held, portable treatment to reverse an opioid overdose. News | Follow @EmilyWFierce

> After a successful IPO, LDR looks to raise more cash. More

> Biotronik proceeds with MRI-safe ICD study in the U.S. as initial patients join in. Story

Pharma News

@FiercePharma: Top-read on FiercePharmaMarketing yesterday: Eli Lilly's sales force finds CRM harmony in the cloud. Story | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. More | Follow @TracyStaton

@EricPFierce: Hikma invested $39M in NJ plant for which FDA has now closed out a warning letter from 2012. News | Follow @EricPFierce

@CarlyHFierce: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. Article | Follow @CarlyHFierce

> Novartis ousts top Japanese execs amid fresh misconduct allegations. More

> More scrutiny, less pay? U.K. docs collected less cash from pharma in 2013. Story

Pharma Manufacturing News

> Apotex plant in India tagged with import ban. News

> Alexion says it will add third operation in Ireland. Story

> Merck puts big data to work to solve vaccine manufacturing concern. Article

> GSK recalls Paxil after FDA issues warning letter. News

> Hikma earns FDA closeout letter for its new Jersey plant. News

> Aurobindo gets control of 7 Actavis API plants in Europe. Brief

Vaccines News

> GlaxoSmithKline admits defeat in PhIII cancer vaccine trial. News

> Mutations during vaccine making weakened last year's flu jab. Story

> GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. Story

> CDC: Flu vaccination cuts children's risk for intensive care hospitalization. Article

> Vaccines sale figures into Baxter's breakup plans. Story

> Trump's Twitter tirade blames vaccines for autism increase. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.